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Abstract
Endometrial carcinoma is the most commonly diagnosed gynaecological cancer in developed
countries. Although the molecular genetics of this disease has been in the focus of many research
laboratories for the last 20 years, relevant prognostic and diagnostic markers are still missing. At
the same time mitochondrial DNA mutations have been reported in many types of cancer during
the last two decades. It is therefore very likely that the mitochondrial genotype is one of the cancer
susceptibility factors. To investigate the presence of mtDNA somatic mutations and distribution of
inherited polymorphisms in endometrial adenocarcinoma patients we analyzed the D-loop
sequence of cancer samples and their corresponding normal tissues and moreover performed
mitochondrial haplogroup analysis. We detected 2 somatic mutation and increased incidence of
mtDNA polymorphisms, in particular 16223C (80% patients, p = 0.005), 16126C (23%, p = 0.025)
and 207A (19%, p = 0.027). Subsequent statistical analysis revealed that endometrial carcinoma
population haplogroup distribution differs from the Polish population and that haplogroup H (with
its defining polymorphism - C7028T) is strongly underrepresented (p = 0.003), therefore might be
a cancer-protective factor. Our report supports the notion that mtDNA polymorphisms establish
a specific genetic background for endometrial adenocarcinoma development and that mtDNA
analysis may result in the development of new molecular tool for cancer detection.
Background
Endometrial cancer (EC) is the most frequently occurring
invasive neoplasm of the female genital tract worldwide
[1,2]. In 2007 approximately 39,000 new cases presented
in the United States and 149,300 in Europe making it the
fourth most common cancer among women. At the same
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from this cancer in USA and 46 600 in Europe annually.
These data enable to calculate that altogether 2.45% of
women born today will be diagnosed with EC at some
time during their lifetime [3,4].
Since 1988, the Gynecologic Oncology Committee of the
International Federation of Gynecology and Obstetrics
(FIGO) has recommended surgical staging of EC based on
exploratory laparotomy, total abdominal hysterectomy,
bilateral salpingo-oophorectomy, peritoneal cytology,
and pelvic and para-aortic lymphadenectomy with the
pathologic stage adding extra information. Unfortunately
staging analysis still does not provide medical doctors,
nor the patient with a relevant prognosis [5]. Multiple
accessory prognostic factors have been defined for
endometrial cancer, also including some molecular mark-
ers [2,6]. Nevertheless still the diagnosis is frequently
uncertain because of false-positive rates of up to 25% and
false-negative rates of up to 10% in cervical invasion eval-
uation with MRI (Magnetic Resonance Imaging) and sen-
sitivity of invasion detection ranging from 66% to 100%
(mean, 86%), and specificity from 92% to 100% (mean,
97%) [7]. Furthermore, the overall quality of surgical stag-
ing may be poor and very different from case to case as it
is related to both the year that the surgeon passed the
license examination and also to specialist status and expe-
rience [8]. It the face of presented data the need for new
medical formation programmes and also novel diagnostic
and prognostic markers is evident. Although endometrial
carcinoma is associated with a good prognosis because
patients tend to present with early disease, high-risk pop-
ulations may benefit from screening, but no prospective
studies have demonstrated a benefit in any population
untill now. Therefore it is interesting to develop new
screening tools that may enable to select populations at
high EC risk and support the process of prevention and
early diagnosis [9]. Until now PTEN (phosphatase and
tensin homolog), K-ras (V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog), TP53 (tumor protein 53), -cat-
enin, MSH2 (MutS homolog 2, colon cancer, nonpolypo-
sis type 2), MSH6 and Her2/neu (Human Epidermal
growth factor Receptor 2); and mitochondrial gene muta-
tions and protein signaling pathways have been impli-
cated in the process of endometrial carcinogenesis
[6,10,11]. On the basis of recent reports, it seems possible
that a molecular mtDNA-analysis-based approach may be
used in clinics in the future [6,12-19].
The first interest in mitochondrial function in carcinogen-
esis was reported as early as in the 1920s, when Otto War-
burg discovered that cancer cells have a high glycolytic
rate and produce increased levels of lactate in the presence
of oxygen. Since then for more than two-thirds of the last
century we have known that a common biochemical sig-
nature of many tumours, particularly those that are poorly
differentiated and proliferate rapidly, is their propensity
to utilize glucose at high rates [20,21]. This cancer charac-
teristic has opened a new field of research today referred
as to "mitochondrial medicine", since mitochondria are
the metabolic organelles of the cells [22,23]. At this point
the mitochondrial genome (mtDNA) came into the focus
of multiple projects. mtDNA somatic mutations were
described to arise in the cells of various types of human
cancers including bladder, brain, breast, colon, head and
neck, lung, ovarian, prostate, or thyroid
[6,12,15,16,18,24-26]. At the same time inherited poly-
morphism have been pointed out as contributing factors
in cancer development [24,27,28]. Nevertheless, the diffi-
cult task of correlating mtDNA polymorphisms and
somatic mutations with neoplastic phenotype is not
solved yet. The key role of the mitochondria in cell apop-
totic pathways and the close link of tumour - suppressor
proteins with mitochondria suggest some of the mecha-
nisms of mitochondria dependent - tumourigenesis
[6,18,19,25,26]. In particular, experiments on nude mice
have shown that alterations in mtDNA (and a subsequent
increase of ROS production) may contribute to cancer for-
mation and development [16,29].
Our current research has been inspired by a number of
studies indicating that mtDNA analysis may be more
powerful in detecting tumour cells in bodily fluids and
cytological specimens than nuclear DNA analysis [17,30].
Fliss and colleagues have reported facile analysis of
mtDNA sequence in diagnostic samples [31]. In the
present study, we examined the distribution of mtDNA
inherited polymorphisms in the D-loop region of mtDNA
in ECs population. Moreover we have also analyzed the
presence of somatic mutations in primary ECs samples. In
addition we have also investigated the distribution of
mitochondrial haplogroups (haplogroup specific poly-
morphisms) in the patient population. Our choice of
complementation of polymorphism analysis by haplo-
group investigation was based on the rationale that the
same mechanisms which may operate to create variation
in evolution can also operate in clonal evolution in
tumours [14]. Finally, in order to test for association with
cancer susceptibility we compared mtDNA-data of EC




Altogether, our analysis on 26 patients has shown that
seven (27%) belong to haplogroup U, five (19%) to hap-
logroup J, four (15%) to haplogroup K, three (12%) to
haplogroup H, two (8%) to haplogroup T and two to hap-
logroup W (8%). No patient of haplogroup I, V or X was
identified. In three (11%) cases, no haplogroup could bePage 2 of 12
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logroup specific positions. Statistical analysis revealed
that EC population haplogroup distribution is different
from distribution found in the general Polish population.
Most striking is the under-representation of haplogroup H
individuals among EC patients (12 vs. 38%; p = 0.003).
Other haplogroups seem to be represented in the cancer
population at a frequency similar to the Polish popula-
tion (Figure 1.).
As haplogroup H is characterized by T7028C polymor-
phism presence we have analyzed its statistical parame-
ters. Patients with endometrial adenocarcinoma had the
T7028C 12% of the time while in the general Polish pop-
ulation [32] carries the T7028C SNP 42% of the time. This
difference is statistically significant p = 0.003 with Fisher's
exact test, which was confirmed both by Yates corrected
chi square χ2 = 7.382 and p = 0.007 and 'N-1' Chi square
χ2 = 8.58 and p = 0.003, and these tests have been used as
expected to give relatively low Type I error. The statistics
was performed as previously suggested [35]. Moreover in
cancer patients T7028C is found at RR = 0.28 (95% CI:
0.093<R.R.<0.812), which is 72% fewer than in non-can-
cer cohort. This gives OR = 0.18 and an inverse OR = 5.53,
which means that one has a 5.53 higher chance to be
T7028C carrier and not develop cancer in comparison to
people who developed cancer, at specificity 0.775 (0.755
- 0.815). 23% more of 7028C do not develop endometrial
adenocarcinoma in comparison to 7028T carriers. Nega-
tive Predictive Value (NPV) of 7028C test result is 0.581
(0.567 - 0.611) with Relative Risk Reduction (RRR) =
0.725 and NND = 5.69. 7028T carriers have RR = 4.51 of
cancer development if compared with 7028C, with OR =
5.5316. The 7028T inheritance correlates with cancer
development with Yules-Q of 0.694, and therefore indi-
cates a moderately strong positive relationship. C7028T
test has sensitivity of 0.885, which guarantees the recogni-
tion of the majority of cancer predisposition as such, thus
a negative result may be used to rule out the disease sus-
ceptibility. High negative predictive value of this test at
0.950 (0.881 - 0.982 at 95% CI) also seems to confirms
the utility of this test. At the same time a relatively low
positive predictive value of 0.223 seems typical for a
multi-factorial disease such as cancer. At the same time
this test is cost-effective, NND is as low as 3.29. Inherit-
ance of 7028T results in RRI of EC development as high as
350% in comparison to 7025C. At the same time ARI is
17.5%.
In face of those calculations 7028C is to have protective
value in EC development with RRR = 78% and ARR =
18%. This percentage of 7028C corresponds to negative
likelihood ratio of 0.225 (0.185 - 0.245 at 95% CI) and is
considered to show a small decrease in the likelihood of
disease. Diagnostic Odds Ratio of C7028T is 5.53 and as
shown before DOR of 3 - 6 is hardly a useful test for diag-
nostic purposes, but it may provide a strong clue in inves-
tigations of etiology [36]. Nevertheless it has to be
underlined that this research must be confirmed on large
sample numbers to verify its relevance for clinical applica-
tion. For evidence based medicine genotyping of a large
number of patients is needed before any application can
be suggested [17,37].
Mutations in the D-loop mtDNA region
In the current study, the mtDNA D-loop sequence was
analyzed by sequencing mtDNA from 26 cancerous and
normal tissues. Both tissues were obtained from the
patients with clinically diagnosed and pathologically con-
firmed EC during surgery. We were able to detect 2
somatic mutations (G16153A and A16188C). These
genetic changes are point mutations and A16188C may be
classified as mtMSI (mitochondrial satellite instability).
As anticipated these mutations are located in mtDNA
hypervariable region I (HV1 - 16024-16383). G16153A is
a transition typically characteristic for mtDNA mutagene-
sis possibly induced by oxidative stress. In contrast,
mtMSI might be generated during erroneous replication.
These mutations seem to be relatively infrequent [12,15]
and therefore possibly are more specific for the EC patient
population.
Germ-line polymorphisms in the D-loop mtDNA region
Our population of patients differs by 80 germ-line poly-
morphisms (Additional file 1; Table S1., Figure 2 and 3)
from haplogroup H [38,39], the most common haplo-
group in Poland, and the haplogroup we have just shown
to be at lower risk for EC development [32,34]. Specifi-
cally only 22 out of 80 (28%) polymorphisms were gen-
erally common [33], and A16T polymorphism has not
been reported previously [34]. We believe that polymor-
phisms uncommon in the global population, but abun-
dant in the endometrial carcinoma cohort are good
Haplogroup distribution in the endometrial adenocarcinoma patient populationFigure 1
Haplogroup distribution in the endometrial adeno-
carcinoma patient population.Page 3 of 12
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ymorphisms were predominantly located in mtDNA
hypervariable regions HV1 (16024-16383, Figure 3) and
HV2 (57-333, Figure 2) - 34 (43%) and 27 (34%) poly-
morphisms, respectively.
Our special attention was aimed at 73, 143, 189, 199, 203,
204, 207, 250, 295, 16051, 16069, 16126, 16129, 16172,
16192, 16223, 16224, 16256, 16270, 16278, 16292,
16311, 16356, 16391 mtDNA position polymorphisms,
as these are D-loop located haplogroup specific loci [40-
42]. This analysis revealed an overabundance of specific
polymorphisms in our cancer study population, in partic-
ular 16126C - specific for J or T haplogroups (p = 0.025);
and 207A - typical for haplogroup W (p = 0.027). At the
same time 16223T, specific for haplogroups W, X and I (p
= 0.005) was underrepresented. In summary 16223C was
present in 80% cases (21/26), 207A was found in 19% (5/
26) and 16126C in 23% (6/26), so there might be a cor-
relation and/or association between 16223C/207A geno-
type and EC development.
A number of patients harboured other unspecific poly-
morphisms, including 73A in patient 402 belonging to
haplogroup T (G specific for haplogroup T), 16356C in
patient 423 belonging to haplogroup U (T specific for
haplogroup U), 16311C in patient 425 belonging to hap-
logroup W (C specific for haplogroups I, K, U, J and H)
and 207A in patient 427 belonging to haplogroup K (G
specific for haplogroup H) (data not shown). These poly-
morphisms would introduced a bias in haplogroup anal-
ysis if no data from RFLP and multiplex-PCR methods
were available, which proves the need for whole-genome
based analysis of haplogroup assignment.
Polymorphisms in the coding region
In addition to D-loop polymorphism, our study reveals
we were also able to detect 11 additional germ-line poly-
morphisms (Additional file 2; Table S2): four in 12S
rRNA, one in ND1, ND2, ND3, CO3, tRNA-Arg, tRNA-
Pro, which differ in our population from rCRS (haplo-
group H). In this analysis polymorphism 4216C affirms
the assignment of patients numbered 401, 403, 409, 410,
418, 428 to haplogroups J and T. Remarkably, position
10463, reported here as polymorphic, has been previously
found subject to somatic mutation in EC by our group
and A15960T has not been reported previously [43].
Discussion
The use of mitochondrial DNA mutation and/or polymor-
phism patterns as a biomarker is rapidly expanding in dis-
ciplines ranging from rare metabolic diseases, aging, to
cancer and the tracing of human migration patterns, pop-
ulation characterization, and human identification in
forensic sciences [12,14,15]. In the case of endometrial
adenocarcinoma the presence of mtDNA mutations has
been analyzed by three independent research groups from
China [44-46], and one from Italy [47]. All those studies
have been rather limited. They included the analysis of:
position 310 (6 cases) [47], nucleotide positions 514,
16189, and 16519 (51 cases) [48], D-loop region, the 12S
and 16S rRNA genes (50 cases) [49], 12 microsatellite
markers starting at nucleotide position 303, 514, 956, and
16184 (17 cases) [50], hypervariable segments of the con-
trol region, parts of 16S rRNA, tRNA(Leu) and ND1 gene
(49 cases) [46]. In summary, all those papers reported one
or more point mutations in 48.4% [50] to 56% of cases
[40] and indicated mononucleotide repeat (D310) as a
mutation 'hot-spot' in primary tumours [47]. In those
reports no correlation between the pattern of mitochon-
drial abnormalities and clinical or histo-pathological fea-
tures was found [47]. The mtDNA analysis of
D-loop nucleotides 1 - 576 polymorphism distribution in endometria  adenocarcinoma patientsFigure 2
D-loop nucleotides 1 - 576 polymorphism distribution 
in endometrial adenocarcinoma patients.
D-loop 16024 - 16569 polymorphism distribution in endometrial adenocarcinoma patientsFigure 3
D-loop 16024 - 16569 polymorphism distribution in 
endometrial adenocarcinoma patients.Page 4 of 12
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noma was not as thorough and only the 16189T>C poly-
morphism was associated with EC susceptibility [48].
EC research [43,51] performed previously in our labora-
tory on a different patient cohort employed SSCP and
eventually subsequent sequencing and covered ~10% of
mtDNA, including nucleotides 135-433, 2986-3301,
4981-5500, 10390-10700 and 12005-12386. In this pre-
viously tested patient cohort, we found homoplasmic
somatic mtDNA mutations in four out of 48 (8%) EC ana-
lyzed. These included alterations in ND2 (G5231A),
ND4L (G10550A, T10640C, T10551C) and tRNAs
(A12308G tRNA-Leu, C12258G tRNA-Ser, T10463C
tRNA-Arg) [43,51]. Our current research on the D-loop
reveals two mtDNA mutations (again only 8% patients)
and shows multiple polymorphisms, including microsat-
ellite instability in the C-tract (between nucleotides 303
and 315) in 22 (85%) of EC patients. The frequency of
mtDNA mutations found in our previous analysis and in
our new patient populations are similar, which strength-
ens the probability of low-mutation load in EC patients.
Also in the report by Schwartz et al. mutations in the mito-
chondrial noncoding polycytidine (C)(n) repeat (polyC)
analyzed in endometrium tumours (n = 53) were present
in 11% of patients [52]. The frequency of D-loop mtDNA
mutations reported by us and Schwartz et al. is much
lower than that reported in other studies where the per-
centage was as high as 32.2% to 56% [49,50]. The fre-
quency of mtDNA mutations in our study also differs
from that reported in other human adenocarcinoma
cases, including mutations found in 37% cases of gastric
tumours [53], 40% - in Barrett's carcinomas [54], and
52% - in prostate cancers [55]. We believe that low
number of mutations we detected is due to the stringent
quality control we used [17,56] and reflects real number
of mtDNA mutations in EC patients. In the light of that we
believe that a great role in cell transformation must be
attributed to inherited mtDNA polymorphisms.
A similar result of high polymorphism rate and low muta-
tion load within cancer cells was reported in prostate [55]
and thyroid cancer [57]. Also the risk of oral cancer was
increased in patients bearing some of the common mito-
chondrial polymorphisms, not the mtDNA mutations
[27]. As many germline mtDNA polymorphisms are
found in the human population [12] it is therefore worth-
while to consider their differential occurrence in cancer-
susceptible population with emphasis on their utility as
potential cancer-predisposition markers [58,59]. In sup-
port of that hypothesis recent large review by the Wallace
group revealed that a major part (72%) of previously
reported tumour-specific somatic mtDNA mutations are
actually mtDNA sequence variants found in the general
population. The authors claim that 52% of the tumour
somatic mRNA missense mutations, 83% of the tRNA,
38% of the rRNA, and 85% of the D-loop mutations are
actually common sequence variants [12]. The report by
Wallace and co-workers seems to favor our results of pol-
ymorphisms analysis.
Our sequencing analysis has been focused on the D-loop
region of mtDNA. The mtDNA D-loop region is highly
polymorphic, contains two hypervariable regions: HV1
(16024-16383) and HV2 (57-333) and was reported as
somatic mutation "hot spot" in many types of cancer [60].
This directed our attention on this mtDNA region. We
need to stress that D-loop contains crucial elements for
mtDNA replication and transcription, and therefore
sequence differences in this region might alter the rate of
DNA replication by modifying the binding affinity of
important trans-activating factors [61]. In fact, both
down- and up-regulation of mtDNA replication was
found in several tumour types [62,63]. Moreover it was
shown that in some cases reduced copy number of
mtDNA correlates with clinical outcome [64] and might
be potentially used to predict prognosis [65]. In the
above-mentioned papers the D-loop sequence variability
was one of key contributing factors leading to decreased
mtDNA level in breast tumours. In particular, the 303-315
stretch highly polymorphic in our patient cohort localizes
in the conserved sequence block II (CBSII) and is the site
of replication primer binding. Although it is not clear
what the long-term impact of mtMSI in this locus is, it is
known that replication efficacy is altered depending on
the sequence length (poly-C polymorphisms), as a result
of CSB II involvement in replication priming. CBSII
heavy-strand contributes to formation of a persistent
RNA-DNA hybrid that serves to prime mtDNA replica-
tion. The formation of RNA-DNA hybrids is dependent on
the GC-rich element. Interestingly, efficient hybrid forma-
tion is also influenced by sequences 5' to the hybrid,
including the CSBIII element [66]. Furthermore mtDNA
transcription required to generate RNA primers used in
the initiation of heavy strand DNA synthesis is critically
dependent on the exact CSB II sequence [67]. Premature
transcription termination occurs if particular mtMSI are
found in positions 300 to 282 of the mtDNA sequence
and may be completely abolished in the 319-289
mutants. In contrast, 304-300 mutants show a drastic
decrease in transcription termination [68]. All these data
support our hypothesis that mtDNA polymorphisms, in
particular D-loop polymorphisms influence cell physiol-
ogy and may result in a pro-carcinogenic phenotype of the
carrier. In addition we believe that the physiological influ-
ence of D-loop (CA)(n) polymorphism is significant in a
clinical perspective, not only in cell biology. This phe-
nomenon was already identified in breast cancer popula-
tion, where patients with multiple alleles of the mtDNA
D-loop (CA)(n) polymorphism (state called hetero-Page 5 of 12
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than those with one allele of the mtDNA D-loop (CA)(n)
polymorphism. This result suggests that the mtDNA D-
loop polymorphisms may be associated with cancer sur-
vival and we believe this might also be true for EC patients
and should be investigated in nearest future [69].
The other position that was highly polymorphic in our
research - 16189 has previously been in the focus of onco-
logical research. The carriers of germ-line T to C polymor-
phism at 16189 are to be more susceptible to breast cancer
and ganglioma development in the light of the high fre-
quency of 16189C detected in cancer patients and low
number of 16189C in healthy individuals [50]. Interest-
ingly, in the report by Liu et al. the T16189C polymor-
phism was found in 14% of ECs. In addition this
polymorphism was also linked with an increased risk of
type II diabetes mellitus, which is well known to be a risk
factor in the aetiology of endometrial and breast cancers
[48,70]. In the screen of female cancers, deletions or inser-
tions were detected in the poly C tract of tumour mtDNA
and were linked in all cases to a germline T to C transition
at 16189. The elimination of the T generates a long poly-
C tract that is generally anticipated to exhibit higher insta-
bility. It was subsequently empirically indicated that this
position represents a strong hotspot of mtMSI with a (C)7-
14 pattern of variation [67]. Furthermore, nucleotides
16184 - 16193 are located on the 3'-end of a termination-
associated sequence (TAS) and at the 7S DNA binding site
which are thought to be involved in the regulation of
mtDNA synthesis [71]. Again if polymorphisms at 16189
are in the focus, our hypothesis of mitochondrial poly-
morphism involvement in cancer development is again
supported in many respects. The second part of our
research focused on mtDNA mutation screen and we have
detected A16188C which is also localized within 16184-
16193 tract involved in the regulation of mtDNA synthe-
sis. This locus was previously reported as mutated in
breast cancer (16188 C→CC) [72] and listed as must-be-
excluded in haplogroup analysis and usage of D-loop
mutations as molecular clock [73].
The CCCCCTCCCC sequences located in the Hypervaria-
ble Regions I and II of the D-loop, but also the 12S rRNA
gene (Additional file 2; Table S2.) emerge as instability
'hot spot' regions in endometrial carcinomas. Considering
other mtDNA polymorphisms reported by us it is worth
noting that some polymorphic sequences within mito-
chondrial tRNA genes (Additional file 2; Table S2.) may
serve as unusual replication origins with pathogenic
implications. Today we know that particular variants of
tRNA genes may acquire secondary structures resembling
mitochondrial origins of light strand replication, particu-
larly structures that might invoke bi-directional replica-
tion. In consequence, this excessive replication may cause
abundant mutations in genome regions not adapted to
tolerate them [74]. At the same time context analysis for
303 polymorphisms revealed a complex influence of
neighbouring bases on mutagenesis in the HVS I region.
Analysis suggested that a transient misalignment disloca-
tion mutagenesis operates in monotonous runs of nucle-
otides and plays an important role in generating base
substitutions in mitochondrial DNA [75]. In our opinion
all discussed mutation/polymorphism generation mecha-
nisms seem to be in important in EC and have potential
impact on cell physiology.
Finally we need to emphesize that as previously pointed
by Salas and Bandelt [76] mtDNA sequencing and analy-
sis techniques contain inherent problems, particularly
with regard to the generation of authentic and useful data.
In fact we understand that for the medical field it is impor-
tant to employ standardized procedures based on scien-
tific grounds, in order to have mtDNA-based evidence
that may be accepted in clinics. Therefore we have put
much effort in refinement of our amplification and
sequencing strategies, as well as a posteriori quality con-
trol of mtDNA sequencing [17,77]. We believe that such
sequencing efforts resulted in low number of mutations,
as we have eliminated phantom mutations [78]. To fur-
ther refine the authenticity of our sequencing results a
posteriori, we utilized the strategy of focused database
comparisons, as this method has been proven to be effec-
tive and successful in the case of modern mtDNA data
[56,76,78]. Considering the critical analysis of mtDNA
sequencing data [76,78] we would like to stress that our
summary (additional file 2; Table S2 and additional file 3;
Table S3.) should be treated and interpreted with caution,
as probaly some previously reported cancer mutations we
cite are actually misreported nucleotide variants [78,79].
The second part of our project covers haplogroup related
polymorphism analysis (Additional file 4; Table S4.). The
frequencies of mtDNA haplogroups vary between ethnic
groups worldwide. Our strictly European population is
exclusively distributed among the nine haplogroups des-
ignated: H, I, J, K, T, U, V, W, and X, whereas haplogroups
A, B, C, D, and E that are characteristic for Asian popula-
tion or haplogroups L1, L2, and L3 specific for the African
population were not analyzed [42]. The research was
inspired by the fact that some haplogroup specific poly-
morphisms are significantly correlated with increased or
decreased risk of specific human disorders, for example -
LHON and Parkinson's disease with haplogroup J [80,81],
ALS with haplogroup I [82], AD in males with haplogroup
U [83], and a significant increase in breast cancer develop-
ment with haplogroup K [84]. Concurrently correlation
between longevity and certain haplogroups (J and U) was
reported [85] (Additional file 4; Table S4.). Those facts
prompt us to think that haplogroup mtDNA variantsPage 6 of 12
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EC. We have chosen to thoroughly analyze haplogroups
in our EC cohort, as polymorphism A5178C - characteris-
tic for haplogroup D (typical for South-East Asia) was cor-
related with the development of EC. The woman carrying
5178C seems to be at a significantly higher risk of EC
development [46]. Nevertheless the Chinese population
has a different mitochondrial genetic background than
the European or white American population, and as a
result A5178C polymorphism - EC correlation is not
exploitable or applicable as a clinical marker outside the
region where it was observed. Until now there was no
reported research on the haplogroup distribution in the
Caucasian EC population (Medline© search database). As
we expected, the EC cohort haplogroup distribution was
not similar to the healthy Polish population with under-
represented haplogroup H individuals among EC
patients. We believe that this might suggest a protective
role of polymorphisms typical for haplogroup H in cancer
development. Our hypothesis seems plausible as mtDNA
haplogroup H is very common in Caucasoids, reaching
frequencies of ~50%, which certainly suggests that it may
confer some advantage. Recent studies have suggested
haplogroup H3 is highly protective against AIDS progres-
sion [13]. Moreover, mtDNA haplogroup H is a strong
independent predictor of outcome during severe sepsis,
conferring a over 2-fold increased chance of survival at
180 days compared with individuals with different haplo-
groups [86].
We believe that inherited mtDNA polymorphisms, both
in the D-loop, and in the coding region (including haplo-
group specific polymorphisms) may cause subtle differ-
ences in the encoded protein structure and function; and
thus subtle changes in OXPHOS activity and free-radical
production. It is therefore likely that mtDNA polymor-
phisms in mitochondrial genes involved in electron trans-
port chain and oxidative phosphorylation result in
increased oxidative stress and hypermutagenesis of mito-
chondrial as well as nuclear DNA. This predisposes an
individual or population sharing the same mtDNA geno-
type to an earlier onset of degenerative cellular processes,
such as the accumulation of somatic mtDNA variation,
decline in OXPHOS capacity or faster cancer progression,
as shown in a cybrid model [87].
Conclusion
In conclusion we suggest that mitochondrial research will
enable to establish bio-markers helping to identify indi-
viduals at high risk for developing specific cancer types
and to develop screening approaches for early diagnosis
of cancer [14,24,84,88]. Molecular assessment of mito-
chondrial abnormalities of cancer cells could represent a
promising tool not only for prognosis and early diagnosis
of neoplasia, but possibly also during the diagnosis or fol-
low-up of cancer patients [15,16,19,89,90]. A number of
studies have proven that the mitochondrial genome is
more useful in detecting tumour cells in bodily fluids and
cytological specimens than mutations in nuclear DNA
[30] in bodily fluids [31] and we believe this can be
applied to EC screening. Thus, we suggest that application
of mtDNA polymorphism pattern analysis may be useful
to select populations at increased risk of cancer develop-
ment and in cancer patients render final diagnosis in
those cases where the morphological abnormalities are
unspecific or neoplastic cells are at difficult to detect. In
those cases, the application of PCR-coupled with gel elec-
trophoresis or DNA sequencing may lend itself to rapid
analysis of multiple samples. In the clinical context, the
high frequency of mitochondrial genome instability, in
combination with PCR-based assays of high sensitivity,
may be of potential clinical usefulness [22,56].
Methods
Patients
Altogether we investigated twenty-seven EC patients who
had undergone surgery (total abdominal hysterectomy
and bilateral oophorectomy) at the IInd Department of
Gynaecology, Medical University at Lublin, Lublin,
Poland, between 2003 and 2006. Pelvic and para-aortic
lymph node dissections were performed if material
obtained at dilatation and curettage was diagnosed as
non-endometrioid or poorly (G3) differentiated cancer,
or when the neoplasm invaded over one-half of the myo-
metrial thickness of the uterus at surgery. In selected cases,
the patients underwent additional surgical procedures,
including omentectomy, appendectomy, tumour cytore-
duction or dissection of distant metastases. Non-neoplas-
tic reference material was available in all cases. The
patients received no chemotherapy, radiotherapy, or hor-
monal therapy before surgery. The clinical stage of the dis-
ease was classified according to the staging system of the
FIGO [91]. The material was assessed histologically at the
Department of Pathology, Medical University in Lublin,
Lublin, Poland, based on the WHO classification [92].
The pathological findings were assessed with regard to
histological type and grade, depth of myometrial infiltra-
tion, pattern of ovarian involvement, vascular space inva-
sion, presence of the neoplastic material in the fallopian
tube, and the presence of metastases in the ovaries and/or
lymph nodes (Additional file 5; Table S5). summarizes
the clinico-pathological features of EC patients enrolled in
this research. The clinical records were reviewed in order
to obtain information regarding patient age, menopausal
status, presenting symptoms and surgical management.
Prior to the surgery, all patients had provided informed
consent to the use of their post-surgical material. The
project was approved by the local Ethics Committee at thePage 7 of 12
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Control group (general Polish population) haplogroup
distribution data has been derived from previous analyses
of Polish population [32,93].
Tissue collection and DNA isolation
At surgery, after the uterus was removed, the uterine cor-
pus was gently cut and the neoplastic material was scraped
to a sterile eppendorf tube. During this procedure, mate-
rial collected from the uterine cavity was not cross-con-
taminated by cervical cells. Tissue obtained at surgery was
sub-divided into two parts. One portion was fixed in buff-
ered formalin (pH 7.4) for routine histopathological
assessment, while the rest was immediately frozen in liq-
uid nitrogen and stored at -80°C. Non-neoplastic material
was also collected at surgery and stored at -80°C until
assayed.
DNA was isolated by standard proteinase K treatment fol-
lowed by phenol/chloroform/isoamyl alcohol extraction.
DNA was precipitated with 0.3 M sodium acetate in 70%
ethanol at -20°C overnight and resuspended in Tris-EDTA
(TE) buffer (pH 8.0). DNA quantification was performed
with measurements at an absorbance of 260 nm.
Mutation and polymorphism analysis
A germline (inherited) polymorphism is described as a
difference between normal tissue variant and the revised
Cambridge Reference Sequence (rCRS) - present both in
normal and tumor tissues. Whenever the change between
sequences from tumor (investigated) sample and normal
tissue occurs, it is defined as a somatic mtDNA mutation.
Obtained alteration frequencies were compared with
mtDB database data [33]. In all positive samples (muta-
tion), sequencing reactions were validated by a new inde-
pendent amplification and sequencing.
Haplogroup analysis by RLFP
Common polymorphisms in mtDNA determining classes
of related genotypes, referred to as haplogroups, were
detected by restriction fragment length polymorphism
(RFLP) analysis. Haplogroup RLFP analysis, restriction
enzymes and primers used are summarized in Additional
file 6; Table S6.
Haplogroup analysis by multiplex-PCR/sequencing
To verify haplogroups established by RFLP (Additional
file 7; Table S7 and Additional file 4; Table S4.), multi-
plex-PCR/sequencing was performed as described previ-
ously [94]. Moreover, haplogroups were also assigned
based on specific D-loop polymorphisms according to
published data [40-42]. If any unspecific RFLP or multi-
plex-PCR/sequencing variants were found, sequencing
with appropriate primers listed in Additional file 8; Table
S8. was performed in order to verify the mutation/poly-
morphism.
PCR amplification of D-loop segment of mtDNA
mtDNA fragment (15587 - 964) containing the D-loop
region (spanning nucleotide 16024 to 576) was amplified
using eight pairs of primers. The primer pairs used and the
sizes of the amplified products are shown in Additional
file 7; Table S7.
Fifty-microlitre reactions contained 10 ng DNA and 0.5
μM primers, 0.2 mM each of deoxynucleotide triphos-
phate (dNTP), 1U of FIREPol® DNA Polymerase (Solis
BioDyne, Estonia) or Pfu DNA Polymerase (Fermentas
AB, Lithuania) and 2.5 mM MgCl2. DNA was subjected to
the following cycling conditions: initial denaturing at
95°C for 3 min followed by 94°C for 1 min, 55°C for 30
sec, and 72°C for 1 min for 40 cycles and final extension
step at 72°C for 7 min. Two microlitres of PCR products
was analysed on an ethidium bromide-stained, 3% agar-
ose gel (40 min at 70 V) to demonstrate the presence of
the amplification product and for its quantification.
mtDNA sequence analysis
Sequence analysis was performed by: FinchTV Version
1.4.0 (Geospiza Inc., USA) and BioEdit version 7.0.5.3
(Copyright Tom Hall 1999-2007), contig assembly was
performed with Sequencher 4.1.4 (Gene Codes Corpora-
tion, Ann Arbor, MI USA) and multiple sequence align-
ment was performed with Clustal W [95]. Normal and
cancer tissue mtDNA sequences were compared with the
revised Cambridge Reference Sequence (CRS) and
sequence variants were recorded [38,39].
Statistical analysis
Two tailed non-directional Fisher-Irwin (Fisher's exact
test) was used for statistical analysis [96]. Statistical anal-
ysis was performed with PAST - PAlaeontological STatis-
tics, ver. 1.34 (Øyvind Hammer, D.A.T. Harper and P.D.
Ryan, 2005) and Analyse-it for Microsoft Excel General &
Clinical Laboratory modules Version 1.73 (Analyse-it
Software, Ltd. Copyright © 1997-2005). The difference was
considered statistically significant if p < 0.05. In selected
cases, to confirm the result Fisher's test, Yates's chi and un-
corrected chi squared test ('N - 1' chi squared test) have
been used as expected to give relatively low Type I error in
case of a small research cohort. The statistics was per-
formed as previously suggested [35]. To further under-
stand the significance of T7028C as a factor for favorable
outcomes (odds ratio, relative risk, difference in propor-
tions, absolute and relative reduction in risk) and of the
effectiveness of a diagnostic criteria (number needed to
diagnose, specificity, positive & negative predictive values,
positive & negative likelihood ratios, diagnostic and errorPage 8 of 12
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confidence intervals for the estimated parameters are
computed by a general method [97,98].
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